The combo was first approved in 2023 for BRCA-mutated metastatic castration-resistant prostate cancer. (Johnson & Johnson) Johnson & Johnson's Akeega is opening new fronts in prostate cancer treatment ...
A great number of DNA-damage repair (DDR) pathways have been recognized to be frequently dysregulated in advanced stages of prostate cancer. DNA-repair defects in prostate cancer represents a ...
Incidence of myelodysplastic syndrome in patients treated with PARP inhibitors: A systematic review.
Investigating the role of immunosurveillance by macrophage in supporting therapeutic strategies using CD47 blockade in MDS. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results